Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial

MLA

M. Martin, et al. “Continued Efficacy of Neratinib in Patients with HER2-Positive (HER2+) Early-Stage Breast Cancer: Final Overall Survival (OS) Analysis from the Randomized Phase 3 ExteNET Trial.” Breast, vol. 56, no. S19-, Apr. 2021. EBSCOhost, https://doi.org/10.1016/S0960-9776(21)00093-X.

APA

M. Martin, F.A. Holmes, B. Moy, J. Mansi, M. Gnant, M. Buyse, C. Barrios, R. Bryce, A. Wong, & A. Chan. (2021). Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. Breast, 56(S19-). https://doi.org/10.1016/S0960-9776(21)00093-X

Chicago

M. Martin, F.A. Holmes, B. Moy, J. Mansi, M. Gnant, M. Buyse, C. Barrios, R. Bryce, A. Wong, and A. Chan. 2021. “Continued Efficacy of Neratinib in Patients with HER2-Positive (HER2+) Early-Stage Breast Cancer: Final Overall Survival (OS) Analysis from the Randomized Phase 3 ExteNET Trial.” Breast 56 (S19-). doi:10.1016/S0960-9776(21)00093-X.